Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wheatley, K.
Right arrow Articles by Ives, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wheatley, K.
Right arrow Articles by Ives, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1319-1320, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Adjuvant interferon for melanoma

K. Wheatley* and N. Ives

University of Birmingham Clinical Trials Unit, Park Grange, Birmingham, UK (E-mail: k.wheatley@bham.ac.uk)

The first 10% of the full text of this article appears below.

In their recent review, Punt and Eggermont [1] state that "combined data from low-dose IFN-{alpha} [interferon-{alpha}] trials does not suggest a benefit in ... DFS [disease-free survival]". This conclusion is inconsistent with the results of a meta-analysis of these trials [2]. It is surprising that Punt and Eggermont [1] do not mention this study, especially as the latter . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?